Novo Nordisk’s Bold Gambit: Price Cuts and Restructuring Amid Market Pressure
Published on 11/20/2025 at 04:01 | Redaktion boerse-global.de
Facing intense competitive pressure, Danish pharmaceutical giant Novo Nordisk is implementing a radical strategic shift. The company has announced dramatic price reductions for its blockbuster drugs Wegovy and Ozempic, coupled with a significant corporate restructuring that will eliminate approximately 9,000 positions globally. This aggressive move comes as Novo Nordisk’s shares have plummeted more than 50% since the beginning of the year.
The market dynamics for GLP-1 medications have transformed considerably, with competitor Eli Lilly gaining substantial ground through its offerings Zepbound and Mounjaro. Market share data reveals the severity of Novo Nordisk’s position: the company’s international GLP-1 business share has collapsed from 71.6% to just 56.3% within a single year.
In Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
